Report prepared by The Clarity Index — Synapse IZ
For informational purposes only. This assessment is generated using AI and publicly available data. It does not constitute investment advice or a recommendation to invest. Independent verification is strongly recommended. Terms of Service ↗
Scientific Validity
Overall Clarity Score
Commercial Viability
Credible with Caveats
Équilibre BioPharmaceuticals' lead asset, EQU-001, is confirmed via ClinicalTrials.gov and a 2025 Epilepsy Research paper (PMID: 41275582) to be ivermectin — a decades-old, off-patent antiparasitic drug — repurposed as an anticonvulsant. This is corroborated independently by a 2023 CNS Drugs review of the epilepsy pipeline (PMID: 37603261), which explicitly names ivermectin as 'an antiparasitic drug currently investigated in a randomised double-blind trial in focal epilepsy,' matching Équilibre's Phase 2 program (NCT05473442) for adjunctive treatment of focal onset seizures, alongside a completed healthy-volunteer PK study (NCT05004571) and a Phase 1 dose-ranging exploratory efficacy study (NCT05063877). Mechanistically, ivermectin's anticonvulsant activity is attributed primarily to positive allosteric modulation of GABA-A receptors, with secondary effects at glycine receptors and glutamate-gated chloride channels — the same broad mechanistic class already exploited by benzodiazepines, barbiturates, and vigabatrin. This is not a first-in-class mechanism. Independent animal studies from different groups (Trailović & Varagić 2008, PMID: 17308985; Dawson et al. 2000, PMID: 11082440; Chern et al. 2025, PMID: 41275582) support anticonvulsant activity across several seizure models, including infantile epileptic spasms syndrome, which is a meaningful and relatively under-served niche. Notably, the Dawson et al. paper flags that anticonvulsant efficacy and CNS toxicity of avermectins both correlate with GABA-A activity, raising a legitimate translational concern about therapeutic window that investors should probe. On the commercial side, the core challenge is that ivermectin is an off-patent generic manufactured cheaply and globally, and marketed for parasitic disease, scabies, and (controversially) repurposed off-label by patients for other indications. No patents specific to an ivermectin epilepsy formulation were identified in this review, meaning Équilibre's defensibility likely rests on method-of-use claims, novel dosing/PK formulations, or regulatory exclusivity (e.g., a 505(b)(2) pathway with orphan designation for IESS) rather than composition-of-matter protection. This is a material commercial risk: even with positive Phase 2/3 data, physicians and payers may question paying premium branded pricing for a drug perceived as a cheap generic, and off-label prescribing could undermine the exclusivity window. Overall, Équilibre occupies a scientifically reasonable but commercially exposed position: it is running real, well-designed multinational Phase 2 trials on a drug with a plausible, multiply-validated (in animals) anticonvulsant mechanism and an established human safety record from other indications, which reduces certain translation risks. However, the mechanism is not novel, the IP position looks thin, and the underlying compound's genericity is a structural commercial headwind that is unusual to see in a well-funded clinical-stage biotech. The regulatory pathway (repurposed approved drug, new indication) is well precedented but the company will need a very clear value proposition (proprietary formulation, orphan exclusivity, novel patient population such as IESS) to justify commercial viability beyond what compounding pharmacies or off-label use could offer.
EQU-001 is confirmed independently across ClinicalTrials.gov listings and peer-reviewed literature to be ivermectin repurposed as an anticonvulsant, acting mainly through GABA-A receptor potentiation with secondary glycine receptor and glutamate-gated chloride channel activity (PMID: 41275582, PMID: 17308985, PMID: 11082440). This mechanism class already underlies multiple approved antiseizure medications, so it is not first-in-class, though application to focal epilepsy and infantile epileptic spasms syndrome via this specific repurposed molecule is a differentiated niche, seemingly unique to this company based on a 2023 pipeline review (PMID: 37603261) that names ivermectin as being tested by only one identifiable developer in this space. Clinical evidence currently consists of completed or ongoing Phase 1 safety/PK and dose-ranging exploratory efficacy studies plus an active multinational Phase 2 RCT in focal onset seizures; no published Phase 2 efficacy results were found in this review. A cautionary signal from older pharmacology work (PMID: 11082440) indicates that anticonvulsant efficacy and CNS toxicity for avermectins may share the same mechanistic driver, which could narrow the therapeutic index and warrants close investor scrutiny of forthcoming Phase 2 safety/efficacy data.
As a repurposed, previously approved drug being studied for a new indication, Équilibre likely has access to a 505(b)(2)-type regulatory pathway in the US, which has well-established precedent for repurposed generics and can shorten certain aspects of development by leveraging existing safety data. However, precisely because ivermectin is off-patent and already approved for other indications, regulatory exclusivity will most likely need to come from orphan drug designation (particularly plausible for infantile epileptic spasms syndrome, a rare pediatric indication) or new-use/formulation patents rather than from the underlying molecule itself. This creates moderate regulatory-commercial risk: the pathway to approval is reasonably clear, but the pathway to durable market exclusivity is less certain and merits direct clarification from the company.
Regulatory risk: Medium
Commercially, Équilibre is repurposing an off-patent generic drug (ivermectin), which is a double-edged sword: strong existing human safety data lowers development risk, but the lack of composition-of-matter IP (no relevant patents were located in this review) and the drug's cheap, globally available generic status raise serious questions about pricing power, payer acceptance, and defensibility against off-label prescribing or compounded alternatives. The epilepsy therapeutics space is moderately crowded with well-funded competitors pursuing GABA-ergic and other mechanisms (darigabat, ENX-101, ETX155, LPCN 2101, STK-001, ETX-101, NRTX-001, NRP2945 per PMID: 37603261), though none appear to be pursuing ivermectin specifically, giving Équilibre a narrow first-mover advantage in this particular repurposing angle. Running a multinational, three-arm, placebo-controlled Phase 2 trial implies non-trivial capital deployment and organizational capability, suggesting the company has secured meaningful funding, though no specific investor or team information was found via available tools. Time to market is realistically 4-7 years assuming Phase 2 success and a subsequent Phase 3 program, with commercial upside constrained unless the company secures orphan designation (e.g., for infantile epileptic spasms syndrome), a novel proprietary formulation, or other regulatory exclusivity mechanisms to counter the generic-drug commercial ceiling.
Time to market
4-7 years, contingent on Phase 2 readout and subsequent Phase 3 program
Capital required
$50-150M through Phase 3 and regulatory filing, given the cost of multinational placebo-controlled trials
Patents filed / granted
0 / 0
Competitor funding
—
Cerevel Therapeutics (darigabat) — Clinical (Phase 2/3)
Subtype-selective GABA-A α2/3/5 modulator, novel chemical entity with composition-of-matter IP, unlike Équilibre's off-patent repurposed drug
Engrail Therapeutics (ENX-101) — Clinical
Subtype-selective GABA-A modulator, proprietary NCE
Stoke Therapeutics (STK-001) — Clinical (Dravet syndrome)
Antisense oligonucleotide restoring NaV1.1/GABAergic interneuron function, disease-modifying approach with strong IP
Encoded Therapeutics (ETX-101) — Clinical
AAV gene therapy for Dravet syndrome, one-time treatment model with strong patent protection
Neurona Therapeutics (NRTX-001) — Clinical
Stereotactically implanted GABAergic interneuron cell therapy for mesial temporal lobe epilepsy, first-in-class cell therapy approach
Équilibre's EQU-001 (ivermectin) occupies a narrow niche within the broader and increasingly crowded GABA-targeting epilepsy pipeline. A 2023 CNS Drugs pipeline review (PMID: 37603261) identifies ivermectin as the only repurposed antiparasitic being tested in a randomized epilepsy trial, alongside other GABA-A positive allosteric modulators (darigabat, ENX-101), neurosteroids (ETX155, LPCN 2101), a repurposed diuretic (bumetanide), and highly differentiated cell/gene therapies (NRTX-001 GABAergic interneuron implantation, STK-001 antisense oligonucleotide, ETX-101 gene therapy) targeting Dravet syndrome and related severe epilepsies. Équilibre's differentiation is thus real but narrow — being effectively the sole company pursuing ivermectin specifically for epilepsy — while facing indirect competition from a wave of better-capitalized, more mechanistically novel candidates (particularly the gene- and cell-therapy approaches) that may command stronger long-term IP and pricing power.
No specific information on the founding team, leadership backgrounds, or prior exits could be located through available research tools. The existence of a completed Phase 1 PK study, a Phase 1 dose-ranging trial, and an active multinational Phase 2 RCT indicates the organization has functioning clinical development and regulatory capability and has raised capital sufficient to run global trials, but independent verification of team credentials, investor identity, and prior track record was not possible with the tools available and should be a priority diligence item.
Funding raised
$47.7M total raised (CB Insights); PitchBook reports $52.6M raised
Key investors
Third Point Ventures
Not yet available.
Not yet available.
Not yet available.
Not yet available.
Not yet available.
Not yet available.
Clarity Score -2.0 — now 4
8/3/2026Between the two score records, Équilibre BioPharmaceuticals Corp.'s commercial viability score fell sharply from 5 to 2, driving the overall clarity score down from 6 to 4, while scientific validity remained unchanged at 7. However, no monitoring reports were logged during this period to document what drove the commercial viability decline. As a result, this change cannot be tied to any specific, verifiable event or finding, and should be flagged for follow-up investigation.
commercial_viability: 5 → 2 — The commercial viability score dropped significantly, but no monitoring reports were logged in this time window to explain the specific cause. This change cannot be substantiated with evidence from the monitoring system.
Unchanged: scientific_validity (No monitoring reports were logged in this window indicating any change to the scientific evidence, IP position, or clinical data, and the score remained at 7.)
Clarity Score — now 6
7/23/2026No structured reason was recorded for this change.
Last reviewed August 3, 2026